Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Cardiology Update from the 2008 ACC Annual Meeting
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Presenters
Facebook Comments